Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Cardiovascular and Interventional Radiology|June 18, 2025
Impact of CT-Assessed Liver Steatosis in Hepatic Regeneration and Surgical Outcome After Liver Venous DeprivationD Santangelo, F Ratti, D Palumbo, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatmentF Rossari, D Lavacchi, E Alimenti, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Comprehensive genetic analysis in biliary tract cancer: a prospective single-center experienceM Rimini, S Presi, K Mohammadi, et al.
ESMO Open|June 18, 2021
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinomaI G Rapposelli, S Shimose, T Kumada, et al.
ESMO Open|November 30, 2021
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinibM Rimini, M Kudo, T Tada, et al.
ESMO Gastrointestinal Oncology|May 22, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort studyH Vandeputte, A Casadei-Gardini, F Peeters, et al.
ESMO Open|October 8, 2022
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysisM Rimini, L Rimassa, K Ueshima, et al.
ESMO Open|July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisS Camera, A Vogel, M Rimini, et al.
Pageof 4